Informed Consent II — The Honest Risks Clinician sign-off

If anyone tells you a psychedelic is "completely safe" or "all natural, so it can't hurt you," they have just told you they cannot be trusted with your life. The honest version is more useful: these medicines can help some people Plausible, and they can also injure or kill — and the gap between those two outcomes is very often screening you can insist on.

The heart is the risk that can end everything

Ibogaine — the highest-acuity example, and the one we use here to teach the principle — disturbs the heart's electrical rhythm. It blocks a channel (hERG) that governs the heartbeat's "reset," stretching out the QT interval; a dangerously long QT can trigger a fatal rhythm called Torsades de Pointes. This is documented, not theoretical: reviewers have recorded deaths at therapeutic doses even in people with no known heart disease, and genetic differences in metabolism raise the danger further^[1].

The numbers are sobering. In a clinical study of 14 people, a single 10 mg/kg dose lengthened the QTc by roughly 95 milliseconds on average, and half of them exceeded a QTc of 500 ms — the threshold clinicians treat as the danger zone for a lethal rhythm — alongside severe, temporary loss of coordination^[2]. Because ibogaine's active byproduct lingers for days, that window of risk can extend well past dosing day^[1].

Your body may not process the dose like anyone else's

How fast you clear a drug is partly written in your genes. A liver enzyme called CYP2D6 varies widely between people, and that variation changes blood levels, effectiveness, and side effects for many medications — including the antidepressants a lot of veterans already take^[3]. A "poor metabolizer" can end up with far higher exposure from the exact same dose. For ibogaine specifically, this is why expert reviewers call for genotyping and monitoring, not a one-size-fits-all dose^[1].

Some of your medications can turn a survivable dose lethal

Interactions raise risk two ways. First, a drug that blocks CYP2D6 (several common SSRIs do) can push the blood level of the psychedelic higher. Second, other drugs — some antibiotics, anti-nausea meds, methadone — can prolong the QT on their own, stacking risk on top of risk.

There is also a distinct, potentially fatal reaction: serotonin syndrome. Combining serotonergic drugs — SSRIs, MAOIs, and serotonergic psychedelics like MDMA — can drive serotonin activity too high, producing autonomic and neuromuscular signs that can kill^[4]. It is diagnosed clinically, and the cornerstone of treatment is stopping the offending drug early and giving supportive care^[5]. MAOIs are especially dangerous — and some plant brews (ayahuasca) contain them.

The psychological risks are real — including in the trials

These are intense experiences. They can surface buried trauma, flood you with fear, or bring a temporary sense of reality coming apart. Risk is higher for anyone with a personal or family history of psychosis or bipolar disorder, which is exactly why psychiatric screening matters.

This isn't fringe alarmism — it shows up in the best studies. In a rigorous phase 2b psilocybin trial (233 people with treatment-resistant depression), a 25 mg dose reduced depression scores more than a 1 mg dose at three weeks Plausible — a real benefit signal — but adverse events occurred in 77%, and suicidal ideation or self-injurious behavior appeared across all dose groups^[6]. A promising result and serious psychiatric risk turned up in the same well-run study. That is why preparation, a trusted setting, and real integration afterward are part of the safety, not optional extras.

What we honestly don't know Hypothesis

We won't fake certainty. We do not yet have proof of long-term outcomes for most people, who benefits most, or how durable any benefit is. The idea that "preparing the body's terrain" or detoxing beforehand improves psychedelic outcomes is a hypothesis, not a proven fact — we are openly studying it, not promising it. The related claim that these drugs deliver a lasting neuroplasticity or BDNF benefit in humans is also unproven; a 2024 human meta-analysis found no change in peripheral BDNF.